Blueprint Medicines’ (BPMC) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $97.00 price objective on the biotechnology company’s stock. Other analysts also recently issued reports about the company. Raymond James raised their […]
More Stories
News from the WHO: WHO Investment Round: culminating moment at G20 Summit as leaders pledge https://ift.tt/dekQnFb November 19, 2024 at 07:00AM
Published on November 19, 2024 at 07:00AM View on website
Insider Selling: Meta Platforms, Inc. (NASDAQ:META) COO Sells 620 Shares of Stock
Meta Platforms, Inc. (NASDAQ:META – Get Free Report) COO Javier Olivan sold 620 shares of the firm’s stock in a...
Nature’s Miracle (NASDAQ:NMHI) Shares Scheduled to Reverse Split on Thursday, November 21st
Nature’s Miracle Holding Inc. (NASDAQ:NMHI – Free Report) shares are set to reverse split before the market opens on Thursday,...
Travis Perkins (OTCMKTS:TVPKF) Sets New 12-Month Low – Here’s Why
Travis Perkins plc (OTCMKTS:TVPKF – Get Free Report)’s stock price reached a new 52-week low on Tuesday . The stock...
Varex Imaging (NASDAQ:VREX) Updates Q1 2025 Earnings Guidance
Varex Imaging (NASDAQ:VREX – Get Free Report) issued an update on its first quarter 2025 earnings guidance on Tuesday morning....
Datadog, Inc. (NASDAQ:DDOG) President Amit Agarwal Sells 150,000 Shares
Datadog, Inc. (NASDAQ:DDOG – Get Free Report) President Amit Agarwal sold 150,000 shares of the business’s stock in a transaction...